The dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice
- 7 August 2024
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (10) , 4613-4621
Abstract
Aim: Tirzepatide (Tzp), a novel dual agonist glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1, is approved for treating insulin resistance and obesity, and menopausal women consuming a high‐calorie diet are a target to study the Tzp effect. Therefore, we aimed to allometrically scale body weight (BW) in Tzp‐treated obese diabetic menopausal mice. Materials and Methods: Three‐month‐old C57BL/6 female mice had bilateral ovariectomy (Ovx) or a sham procedure and for 12 weeks were fed a control diet or a high‐fat and high sucrose diet ( n = 120/each group [control (C), obese diabetic (Od), Ovx (O), sham (S), Tzp (T)]). Tzp was subcutaneously administered (10 nmol/kg) or vehicle once a day for an additional 4 weeks. The analysis considered log‐transformed data and the allometric equation log y = log a + b log x . Results: Od and OdO showed more upward slopes than C and CO. In C, BW was non‐allometric by T administration. Od and OdO showed slightly positive slopes (more prominent in OdO than Od). OdT and OdOT showed negative slopes, significant intercepts, and more robust Pearson coefficients than untreated ones. A potent drug effect was seen with BW allometric decline. Interactions between diet versus Ovx and diet versus Tzp affected weight gain. Diet versus Ovx versus Tzp affected food intake. Conclusions: A model was developed to show three usual factors observed in mature women. Notably, Tzp improved the metabolism and weight loss of OdO mice. Tzp‐treated mice showed negative allometric BW across treatment time, which is a quantitative assessment that allows better comparison between results.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (302215/2022‐0, 305993/2021‐6)
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (E‐26/200.796/2021, E‐26/200.936/2021, E‐26/201.857/2020, E‐26/205.749/2022)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Finance code 0001)
This publication has 39 references indexed in Scilit:
- A Bayesian model‐based reduced major axis regressionBiometrical Journal, 2024
- Obesity and menopauseBest Practice & Research Clinical Obstetrics & Gynaecology, 2023
- Challenging obesity and sex based differences in resting energy expenditure using allometric modeling, a sub-study of the DIETFITS clinical trialClinical Nutrition ESPEN, 2022
- Semaglutide (GLP‐1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese miceCell Biochemistry and Function, 2022
- Pancreatic islet cells disarray, apoptosis, and proliferation in obese mice. The role of Semaglutide treatmentBiochimie, 2022
- Vitamin D deficiency aggravates the liver metabolism and inflammation in ovariectomized miceBiomedicine & Pharmacotherapy, 2018
- Effects of liraglutide in hypothalamic arcuate nucleus of obese miceObesity, 2016
- Subcutaneous adipose tissue insulin resistance is associated with visceral adiposity in postmenopausal womenObesity, 2014
- Adiponectin mRNA in adipose tissue and its association with metabolic risk factors in postmenopausal obese womenHormones, 2013
- Consequences of genetic manipulations of gonadotrophins and gonadotrophin receptors in miceAnnales d'Endocrinologie, 2010